Page 13 - Shai Biran News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression. Clinical trials expected to initiate in the second half of 2021 Effector control technologies give new potential for enhancing current and future immunotherapies while reducing toxicities ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 10, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the presentation of four posters highlighting research across its immuno-oncology programs at the American Association for Cancer Research (AACR) virtual Annual Meeting. The preclinical data shared include results from the Company s acute myeloid leukemia (AML) CD3 T-cell engager program, new data fro

United statesShai biranProdrug darpinSeth lewisThomas schneckenburgerDaniel steinerAmerican association for cancer researchResearch of molecular partnersCompany on twitter at molecularprtnrsMolecular partnersAmerican associationCancer researchScientific presentationsMolecular partnerஒன்றுபட்டது மாநிலங்களில்ஷாய் பிரன்